Shanghai Vitalgen Biopharma Co., Ltd.

This early-stage study is testing a new gene therapy called VGN-R08b for Parkinson's disease in people who have a specific genetic change (GBA1 mutation). The therapy is injected directly into the fluid around the brain. The main goals are to first check if it's safe and tolerabl…